• WHO validates Sinovac COVID-19 vaccine for emergency use

    WHO validates Sinovac COVID-19 vaccine for emergency use

    WHO News–

    World Health Organization (WHO ) validated the Sinovac-CoronaVac COVID-19 vaccine for emergency use, giving countries, funders, procuring agencies and communities the assurance that it meets international standards for safety, efficacy and manufacturing. The vaccine is produced by the Beijing-based pharmaceutical company Sinovac.

    “The world desperately needs multiple COVID-19 vaccines to address the huge access inequity across the globe,” said Dr Mariângela Simão, WHO Assistant-Director General for Access to Health Products. “We urge manufacturers to participate in the COVAX Facility, share their knowhow and data and contribute to bringing the pandemic under control.”

    WHO’s Emergency Use Listing (EUL) is a prerequisite for COVAX Facility vaccine supply and international procurement. It also allows countries to expedite their own regulatory approval to import and administer COVID-19 vaccines.

    The EUL assesses the quality, safety and efficacy of COVID-19 vaccines, as well as risk management plans and programmatic suitability, such as cold chain requirements. The assessment is performed by the product evaluation group, composed by regulatory experts from around the world and a Technical Advisory Group (TAG), in charge of performing the risk-benefit assessment for an independent recommendation on whether a vaccine can be listed for emergency use and, if so, under which conditions.

    In the case of the Sinovac-CoronaVac vaccine, the WHO assessment included on-site inspections of the production facility.

    The Sinovac-CoronaVac product is an inactivated vaccine. Its easy storage requirements make it very manageable and particularly suitable for low-resource settings.

    WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) has also completed its review of the vaccine. On the basis of available evidence, WHO recommends the vaccine for use in adults 18 years and older, in a two-dose schedule with a spacing of two to four weeks. Vaccine efficacy results showed that the vaccine prevented symptomatic disease in 51% of those vaccinated and prevented severe COVID-19 and hospitalization in 100% of the studied population.

    Few older adults (over 60 years) were enrolled in clinical trials, so efficacy could not be estimated in this age group. Nevertheless, WHO is not recommending an upper age limit for the vaccine because data collected during subsequent use in multiple countries and supportive immunogenicity data suggest the vaccine is likely to have a protective effect in older persons. There is no reason to believe that the vaccine has a different safety profile in older and younger populations. WHO recommends that countries using the vaccine in older age groups conduct safety and effectiveness monitoring to verify the expected impact and contribute to making the recommendation more robust for all countries.

    WHO emergency use listing

    The emergency use listing (EUL) procedure assesses the suitability of novel health products during public health emergencies. The objective is to make medicines, vaccines and diagnostics available as rapidly as possible to address the emergency, while adhering to stringent criteria of safety, efficacy and quality. The assessment weighs the threat posed by the emergency as well as the benefit that would accrue from the use of the product against any potential risks.

    The EUL pathway involves a rigorous assessment of late phase II and phase III clinical trial data as well as substantial additional data on safety, efficacy, quality and a risk management plan with a focus on low- and middle-income country needs. These data are reviewed by independent experts and WHO teams who consider the current body of evidence on the vaccine under consideration, the plans for monitoring its use, and plans for further studies.

    As part of the EUL process, the company producing the vaccine must commit to continue to generate data to enable full licensure and WHO prequalification of the vaccine. The WHO prequalification process will assess additional clinical data generated from vaccine trials and deployment on a rolling basis to ensure the vaccine meets the necessary standards of quality, safety and efficacy for broader availability.

    WHO has already  listed the Pfizer/BioNTech, Astrazeneca-SK Bio, Serum Institute of India, Astra Zeneca EU, Janssen, Moderna and Sinopharm vaccines for emergency use.

    June 2021

    Image : A vial of the Oxford/AstraZeneca COVID-19 vaccine . – WHO

    • Connecting you with the world of travel and tourism

      Theme Park Expo Vietnam 2025

      Asia Pool & Spa Expo , May 10 – 12, 2025 , Guangzhou , China

      KAZAKHSTAN International Exhibition “Tourism & Travel” Almaty, Kazakhstan

      CHINA- Beyond your imagination

      Gulf Cooperation Council Tourism 

      Dubai – As tourism destinations in the Gulf Cooperation Council (GCC) continue to grow, involving local communities in destination development has become increasingly vital for long-term success.

      Abu Dhabi’s Tourism Strategy 2030 aims for 39.3 million visitors per year, while Saudi Arabia’s Vision 2030 targets 150 million domestic and international visits, emphasising how tourism is being established as a key element of economic diversification throughout the region.

      At Arabian Travel Market (ATM) 2025, industry leaders emphasised that sustainable revitalisation of destinations must align tourism investments with community partnerships, cultural authenticity, and immersive guest experiences to provide lasting value for both residents and visitors.

      During the session on “Considerations and Implications of Involving Communities in Destination Revitalisation” on the ATM 2025 Global Stage, experts shared insights into building resilience, enhancing local prosperity, and ensuring tourism growth is both inclusive and enduring.

      Arabian Travel Market 2025, held under the theme “Global Travel: Developing Tomorrow’s Tourism Through Enhanced Connectivity”,  featured more than 200 speakers across three content stages and welcomes over 55,000 travel professionals from 166 countries.

      Messe Berlin India launched 

      to drive growth of ITB India 

      Messe Berlin announces the official launch of Messe Berlin India, a newly incorporated subsidiary that underscores the company’s long-term commitment to one of Asia’s fastest-growing markets. Headquartered in Delhi , the new entity will serve as a strategic base for expanding ITB India and launching future projects tailored to the Indian market. With this establishment, Messe Berlin is reinforcing its vision of India as a regional hub for innovation, collaboration, and sustainable business growth within the exhibition and events industry.

      “Messe Berlin’s presence in India reflects our strategic intent to strengthen our international reach by being where the growth is. India is a key market for us — vibrant, diverse, and full of opportunities. With Messe Berlin India, we are laying down long-term foundations to build strong partnerships, support local industries, and elevate our global platforms,” said Dr. Mario Tobias, CEO, Messe Berlin.

      ITB India, inaugurated in 2023, continues as the flagship event under the new subsidiary. Held annually, ITB India is a three-day B2B travel trade show and convention that connects the global travel and tourism industry with the Indian market. Alongside MICE Show India, Travel Tech India, and the ITB India Conference, ITB India serves as a unique platform to forge new partnerships, strengthen existing ties, and capitalize on the fast-growing potential of the Indian and South Asian travel economies. The show hosts key players from the MICE, Leisure, Corporate Travel, and Travel Technology sectors. The upcoming edition, ITB India 2025, will take place from 2 – 4 September 2025  in Mumbai.

      FACTS —

      Tourism helps in:

      👉Reducing poverty

      👉Reducing Inequalities

      👉Promoting gender equality

      👉Fostering decent work and economic growth

      World Tourism Day 2021: ‘Tourism for Inclusive Growth’

      In 2019, Travel & Tourism’s direct, indirect and induced impact accounted for:
      -US$8.9 trillion contribution to the world’s GDP
      -10.3% of global GDP
      -330 million jobs, 1 in 10 jobs around the world
      -US$1.7 trillion visitor exports (6.8% of total exports,
      28.3% of global services exports)
      -US$948 billion capital investment (4.3% of total
      investment)

      Best Tourism Villages 2024

      ” Nihao ! China ” Silk Road Tourism